Latest news with #JamieMoses
National Post
03-07-2025
- Health
- National Post
Bioscience Association Manitoba Applauds Government Action to Advance Bioscience Research and Clinical Trials in Manitoba
Article content WINNIPEG, Manitoba — Bioscience Association Manitoba (BAM) welcomes the Manitoba government's latest announcement to launch a Clinical Trials Office, and the implementation of the Research Manitoba led project, Research Improvements Through Harmonization in Manitoba (RITHIM), both designed to accelerate and improve health research in the province. Article content 'For too long, the process of moving innovative research into real-world care has taken longer in Manitoba than in other jurisdictions,' said Andrea Ladouceur, President & CEO of BAM. 'Both the new Manitoba Clinical Trials Office and RITHIM are key pieces of the puzzle that will help connect research to our ecosystem and shorten timelines and enables research to get where it's needed, into the lives of Manitobans.' Article content Manitoba has led with action on the top 2 recommendations from the Manitoba Clinical Trials Working Group. The first is to create a Clinical Trials office to champion connections between researcher and resources and the second is to create a timebound standardized processes. Article content BAM was honoured to co-chair this Working Group over the past 10 months developing recommendations to improve how research is conducted in the province. Article content The new Manitoba Clinical Trials Office, announced by Honourable Jamie Moses, Minister of Business, Mining, Trade, and Job Creation, will help champion Manitoba as a destination for world-class clinical research. RITHIM will also help shorten process timelines. Learn more at Article content 'Clinical trials are essential to getting new, innovative medicines into our healthcare system,' noted Ladouceur. 'Canada uses only about 20 per cent of the innovative medicines available in other G7 countries. Manitoba can and should lead the way in changing that.' Article content The bioscience sector contributes approximately 7 per cent of Manitoba's GDP, with medicine ranked as the province's top export. Manitoba is home to a growing hub of companies like Bausch Health, Pfizer, Cytophage Technologies, Emergent, Kane Biotech, and Dynacare, which are developing solutions that help patients return to healthier lives. Article content 'Our members are leaders in how we heal, feed, and fuel the world,' said Ladouceur. 'But innovation only matters if it reaches people. Many patients can't wait for life-saving treatments. That's why we need to continuously improve how we move research from the lab into people's lives,' noted Andrea. Article content With this announcement, BAM sees Manitoba taking a strong step forward toward a more coordinated, responsive, and globally competitive research environment. Article content 'We're proud to support this important milestone,' added Ladouceur. 'Manitoba is the right place for research to thrive with strong values around inclusivity, a commitment to quality, and a collaborative mindset. We look forward to what comes next.' Article content Bioscience Association Manitoba (BAM) is a not-for-profit industry association that enables commercial success for bioscience companies in Manitoba by acting as a catalyst for innovation, leading with one unified voice for all bioscience advancement and growth, and supporting a future-focused workforce. Article content Article content Article content Article content Article content Article content
Winnipeg Free Press
03-07-2025
- Business
- Winnipeg Free Press
Manitoba seeks to grow innovation, investment in bioscience sector
The province is launching a new clinical trials office to fast-track health research and creating an initiative to grow Manitoba's bioscience sector. Research Improvements Through Harmonization in Manitoba (RITHIM) will bring industry partners together to streamline the review system so research projects can be approved faster and more efficiently. The new electronic system will also create a single co-ordinated application process. MLAs Renée Cable, Jamie Moses and Mike Moroz made the announcement Wednesday at Red River College Polytechnic's Notre Dame Avenue campus in Winnipeg. MIKE DEAL / FREE PRESS Advanced Education and Training Minister Renée Cable speaks at a press conference Wednesday with fellow ministers, Innovation and New Technology Minister Mike Moroz, left, and Business, Mining, Trade and Job Creation Minister Jamie Moses at the RRC Simulation Centre, where they announced the provincial government's launch of a new clinical trials office to fast-track health research and the new Research Improvements Through Harmonization in Manitoba (RITHIM) project to grow Manitoba's bioscience sector. RITHIM and the clinical trials office will make it 'easier, faster and more efficient' for innovation and investment in the biosciences field in Manitoba, said Cable, the advanced education and training minister. It will create jobs and signal to students in Manitoba there is a space for people who want to work in biosciences and do cutting-edge research in the province, she added. The clinical trials office will build on Manitoba's strength as Canada's second-largest pharmaceutical exporter and a hub for biotech innovation, said Moses, who noted Manitoba's biosciences sector adds $5.2 billion to the provincial GDP. 'We have a homegrown network of researchers (and) innovators … that are thriving and driving innovation and new health-care diagnostics and therapeutics right here in Manitoba,' said Moses, the business, mining, trade and job creation minister. 'This clinical trial office will help us leverage their success to even more strengths and success in the future and, on top of that, will attract new investment into our province.' Research Manitoba, the provincial agency that promotes the funding of research, will lead RITHIM. RITHIM director Liz Lylyk described the initiative as unique across Canada and said it will harmonize ethics, privacy and health institutional review processes to streamline health research approvals in Manitoba. The project will create an ecosystem where researchers can focus on science, accelerate innovation and get solutions to the population faster, Lylyk said. 'RITHIM will be an essential element of growing health research here in Manitoba, leading to economic and social prosperity, as well as significant improvements in the health and well-being of Manitobans.' The province's biosciences sector is largely unknown but delivers more than 14,000 jobs to Manitobans, said Andrea Ladouceur, Bioscience Association Manitoba president and CEO. 'Research can have a long runway in its pursuit of being available to all,' she said. 'RITHIM is a key component in helping us make sure that that process is done properly and within reasonable timelines.' The government is investing $100,000 this year in the new clinical trials office, Moses said. The investment is part of Manitoba's 2025-26 budget. Monday Mornings The latest local business news and a lookahead to the coming week. RITHIM and the clinical trials office will create more opportunities for businesses to invest in Manitoba, Moses added. 'Not only is this a signal that we're ready to break down barriers to make sure investment happens in Manitoba quicker, but we're also able to work in partnership with industry to understand their needs, listen to them and make sure that we take concrete action to make sure our Manitoba economy continues to grow,' he said. 'At the same time, it's going to improve health-care outcomes for Manitobans.' Wednesday's briefing followed last month's announcement the province is giving Research Manitoba an annual $5-million funding top-up. Aaron EppReporter Aaron Epp reports on business for the Free Press. After freelancing for the paper for a decade, he joined the staff full-time in 2024. He was previously the associate editor at Canadian Mennonite. Read more about Aaron. Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Yahoo
24-06-2025
- Business
- Yahoo
FHB Q1 Deep Dive: Deposit Cost Management and Economic Uncertainty Shape Outlook
Hawaiian banking company First Hawaiian (NASDAQ:FHB) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 2.5% year on year to $211 million. Its non-GAAP profit of $0.47 per share was in line with analysts' consensus estimates. Is now the time to buy FHB? Find out in our full research report (it's free). Revenue: $211 million vs analyst estimates of $209.7 million (2.5% year-on-year growth, 0.6% beat) Adjusted EPS: $0.47 vs analyst estimates of $0.46 (in line) Market Capitalization: $3.02 billion First Hawaiian's first quarter results saw stable performance, with management attributing revenue growth to disciplined deposit cost management and effective repositioning of the investment portfolio. CEO Bob Harrison noted that net interest income benefited from a decline in deposit costs and continued healthy credit quality. The bank's retail deposit growth offset fluctuations in commercial accounts, and asset quality metrics remained strong, with classified assets and net charge-offs both low. Management acknowledged increased macroeconomic uncertainty but emphasized that credit performance was in line with expectations. Harrison also highlighted, 'We continue to be well capitalized with ample liquidity.' Looking forward, First Hawaiian's leadership anticipates ongoing uncertainty in the economic environment, particularly due to questions around tariffs, visitor arrivals, and consumer confidence. CFO Jamie Moses stated that while the underlying balance sheet dynamics supporting net interest margin remain intact, the ability to further reduce deposit costs is limited outside of upcoming certificate of deposit repricings. The company expects loan growth opportunities depending on broader economic conditions, but management is cautious about the timing and impact of potential rate cuts and changing customer behaviors. As Harrison put it, 'There's more uncertainty in the market…we certainly can't tell what's going to happen in the back half of the year.' Management attributed the quarter's results to lower deposit costs, steady loan demand, and conservative credit practices, while highlighting increased uncertainty from external economic factors. Retail deposit growth: The bank saw a notable increase in retail deposits, which management credited to strong performance from branch teams and deeper customer relationships. This growth helped offset declines in commercial deposit balances, which management described as normal fluctuations among large accounts rather than a sign of broader weakness. Deposit cost management: CFO Jamie Moses highlighted the benefit from lower deposit costs, driven by both the pricing in of prior rate cuts and the ongoing repricing of certificates of deposit (CDs). Management acknowledged that further reductions in deposit costs may be limited, except for remaining CD repricings later in the year. Loan portfolio trends: Total loans declined modestly, mainly due to scheduled and early payoffs in commercial real estate and typical seasonal reductions in dealer floor plan balances. However, management emphasized a healthy loan pipeline and expressed optimism about potential loan growth, subject to economic conditions and uncertainty around tariffs. Expense discipline: Operating expenses were well controlled in the quarter, coming in below expectations. Management reiterated its commitment to balancing investment in technology and staff with overall expense guidance for the year, noting that large-scale tech investments have tapered off following prior years of elevated spend. Credit quality resilience: Chief Risk Officer Lea Nakamura reported that credit risk remains stable and within expectations, with low levels of nonperforming assets and net charge-offs. The bank increased its allowance for credit losses due to a more cautious economic outlook, but has not observed broad signs of credit deterioration across its portfolios. First Hawaiian's outlook is shaped by sustained margin discipline, the pace of loan growth, and the potential impact of external economic headwinds. Limited deposit cost flexibility: Management expects that most of the benefit from deposit repricing has already been realized, with remaining opportunities largely tied to upcoming CD maturities. This may limit further margin expansion unless market interest rates decline more than anticipated. Loan growth tied to economic outlook: While there is a healthy pipeline of potential loans, actual growth depends on economic conditions, including the effects of tariffs on local businesses and ongoing uncertainty in both the tourism and construction sectors. Management maintained a cautious stance, stating that loan growth could reach low- to mid-single digits for the year if conditions remain supportive. Expense and credit vigilance: The company plans to keep expenses within guidance while being prepared to invest in targeted projects if warranted by the economic outlook. Credit risk teams are closely monitoring portfolios potentially sensitive to tariffs and supply chain disruptions, especially among commercial borrowers in affected industries. In the coming quarters, our analysts will be closely watching (1) whether loan growth rebounds as expected, particularly in commercial and consumer sectors; (2) the impact of upcoming CD repricings and any further movement in deposit costs on net interest margin; and (3) how external factors like tariffs and tourism trends affect local economic activity and credit quality. The pace and effectiveness of targeted investments in technology and customer service will also be key to tracking ongoing competitiveness. First Hawaiian Bank currently trades at $24.05, up from $23.30 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Winnipeg Free Press
16-06-2025
- Business
- Winnipeg Free Press
MB tabs $640K via Innovation Growth Program
The Manitoba government has announced more than $640,000 for local companies' growth and product innovation. Nine companies have received funding through the Innovation Growth Program, Economic Development Minister Jamie Moses said in a news release Monday. Through the program, small- and medium-sized companies receive cost-shared grants up to $100,000. Businesses in this round of funding expect to collectively add more than 100 new full-time jobs and $36.1 million in export sales over the next five years. CEMWorks Inc. netted a $100,000 grant toward commercialization of an electromagnetic simulation software tool, and iSBERGDATA received the same amount for commercialization of an electronic health-care record and health information management system. Moonlite Media Inc. will use $75,000 to commercialize Moonlite Labs, its animation creation platform; and True Ag Developments Inc. has tabbed its $50,000 to support promotion and market-outreach efforts for its proprietary financial technology platform, ProHog Financial. Phason Controls, Polywest Ltd., Precision ADM, Thunderstruck Ag Equipment and TooPink Creative also received grants. The deadline for the next Innovation Growth Program's current intake is June 30. — Free Press staff
Winnipeg Free Press
14-06-2025
- Business
- Winnipeg Free Press
Manitoba trade council meets
Manitoba's trade council met Friday to discuss the province's ongoing trade relationship with the United States. Premier Wab Kinew announced the meeting in a news release, adding it featured discussion about the province's ongoing wildfire situation and a report back from the first ministers meeting. Business, Mining, Trade and Job Creation Minister Jamie Moses updated the council on the passage of Manitoba's free trade legislation, new legislation to make it easier to trade with other provinces and territories, new funding to support research and attract American talent to Manitoba and the province's work with Selkirk's Gerdau steel mill to mitigate the impact of new steel tariffs. The province continues to offer tax deferrals for businesses affected by tariffs and wildfires. Formed in January, the trade council includes more than a dozen leaders from the private sector, business associations and labour groups. — Free Press staff
